6月5日至11日，美国药品研究与制造企业协会（PhRMA）全球副总裁何凯文博士（Dr. Kevin Haninger）来访中国。在为期一周的时间里，何凯文博士会见了成员企业代表、政府领导、知名高校和智库等合作伙伴及各相关方，并同中国国际经济交流中心及中国发展研究基金会展开了深入交流。何凯文博士代表PhRMA参加了许多卓有成效的会议，以推动生物制药创新生态体系建立，进一步促进提升中国患者的创新药物可及性。

The Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President Dr. Kevin Haninger visited China from June 5-11, meeting with member company representatives, senior government officials, local university and think tank partners, and other stakeholders. The visit included meetings with the China Center of International Economic Exchanges (CCIEE) and the China Development Research Foundation (CDRF). Dr. Haninger represented PhRMA in participating in fruitful meetings with multiple partners to strengthen the biopharmaceutical innovation ecosystem. The visit was productive and significant in advancing PhRMA’s mission to further improve access to innovative medicines for Chinese patients.

何凯文博士和PhRMA中国办公室会见成员企业代表

Dr. Kevin Haninger meeting with colleagues from member companies

中国国际经济交流中心会见何凯文博士和PhRMA中国办公室

Dr. Kevin Haninger and PhRMA China Office meeting CCIEE

何凯文博士和PhRMA中国办公室访问清华大学，并出席商业健康险与医药协同创新模式研究课题成果研讨会

Dr. Kevin Haninger and PhRMA China Office visiting Tsinghua University and attending Seminar on "Collaborative Innovation Model between Commercial Health Insurance and Pharmaceutical Companies."

何凯文博士在第六届中国多层次医疗保障体系创新高峰论坛开幕式上致辞

Dr. Kevin Haninger addressing the 6th China Multi-level Medical Security System (MLSS) Innovation Summit Forum

何凯文博士及PhRMA中国办公室同中国发展研究基金会访问珠海市城市定制型商业医疗保险（惠民保）服务站

Dr. Kevin Haninger and PhRMA China Office visiting City-specific Commercial Health Insurance” (CSCHI) service station with CDRF in Zhuhai City

关于我们

美国药品研究与制造企业协会（PhRMA）代表全球领先的创新生物制药研发公司，致力于通过推动新药研发，帮助患者过上更长寿、更健康和更具活力的生活。自2000年以来，PhRMA成员公司已投入超过1.1万亿美元用于开发新的治疗方案；仅2021年一年，投入就高达1023亿美元。PhRMA中国办公室及中国执行联络组全力推进生物制药创新生态发展，持续提升患者的创新药物可及性。

About Us

PhRMA represents global leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than $1.1 trillion in the search for new treatments and cures, including $102.3 billion in 2021 alone. In Beijing, the PhRMA China Office and the China Executive Liaison Team strive to further advance the biopharmaceutical innovation ecosystem and improve patient access to innovative medicines.